In Brief: Searle
Executive Summary
Searle: HIV protease inhibitor patents and compounds being made available for licensing. Searle, which has discontinued research of protease inhibitors, is in discussions with several major pharmaceutical firms regarding patent licensing agreements and co-development of two lead protease inhibitor compounds. Glaxo and Vertex recently paid Searle $25 mil. for non-exclusive license to several patent applications and future royalties on experimental protease inhibitor 141W94 (VX-478) to be able to market the product free from intellectual property claims by Searle...